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Neural progenitor cells are widespread throughout the adult cen-
tral nervous system but only give rise to neurons in specific loci.
Negative regulators of neurogenesis have therefore been postu-
lated, but none have yet been identified as subserving a significant
role in the adult brain. Here we report that nitric oxide (NO) acts
as an important negative regulator of cell proliferation in the adult
mammalian brain. We used two independent approaches to ex-
amine the function of NO in adult neurogenesis. In a pharmaco-
logical approach, we suppressed NO production in the rat brain by
intraventricular infusion of an NO synthase inhibitor. In a genetic
approach, we generated a null mutant neuronal NO synthase
knockout mouse line by targeting the exon encoding active center
of the enzyme. In both models, the number of new cells generated
in neurogenic areas of the adult brain, the olfactory subependyma
and the dentate gyrus, was strongly augmented, which indicates
that division of neural stem cells in the adult brain is controlled by
NO and suggests a strategy for enhancing neurogenesis in the
adult central nervous system.
The vast majority of neurons in the mammalian brain areproduced during embryonic development. However, rem-
nants of the germinal zones of the developing brain continue to
proliferate into adulthood, generating large numbers of neurons
in the adult brain (1–3). The subventricular zone (SVZ) of the
lateral ventricles (LVs), its anterior extension, the rostral mi-
gratory stream (RMS), and the subgranular cell layer (S-GCL)
of the dentate gyrus (DG) of the hippocampus are the major
sites of adult neurogenesis, although other regions of the adult
brain retain the potential to generate new neurons (4–6). Many
of the newly generated neurons undergo physiological cell death
(7), but it is becoming clear that some of these new neurons
become integrated into existing neuronal circuits, thus poten-
tially contributing to a previously unanticipated form of neuro-
plasticity (8). Several protein growth factors have been shown to
affect adult neurogenesis in vivo (5, 6, 9–11). However, the
signaling systems involved in regulating cell division in the adult
brain are only beginning to be understood.
Increasingly diverse functions of NO, a transcellular signaling
molecule (12), are continuing to be demonstrated, and there is
growing evidence that NO may be involved in controlling
proliferation of neuronal cells. Neuronal NO synthase (nNOS),
the major NOS isoform in the mammalian brain, is transiently
expressed in the developing brain in a pattern suggesting its
involvement in neural development (13). Furthermore, NO has
been shown to effectively and reversibly suppress cell division
(14, 15); this property of NO, coupled to its ability to regulate
gene expression, is exploited in a number of developmental
contexts (16).
Materials and Methods
A full description of the methods used in this work can be found
in Supporting Materials and Methods, which is published as
supporting information on the PNAS web site, www.pnas.org.
All animal procedures were performed under National Insti-
tutes of Health guidelines for the care and use of animals in
research and approved by the animal care and use committees
of the host institutes.
Surgical Procedures and BrdUrd Administration. Osmotic mini-
pumps were used to infuse 50 mM N-nitro-methyl-L[D]-arginine
methyl ester (NAME) into the LV of Sprague–Dawley rats.
BrdUrd was administered i.p. to rats (120 mgkg) twice daily for
7 days starting on the day after surgery or twice daily for 2.5 days
to mice (50 mgkg).
Histochemistry. At various time points animals were perfused
transcardially, and the brains were fixed and sectioned on a
cryostat by using standard procedures. Diaphorase reaction and
immunohistochemistry were performed by using standard meth-
ods. Immunohistochemistry with rabbit anti-nNOS (Z-RNN3,
Zymed), anti-BrdUrd antibody [rat ascites, clone BU1
75(ICR1) Harlan Laboratories, Haslett, MI], mouse anti-III-
tubulin (clone 5G8, Promega), or mouse anti-glial fibrillary
acidic protein (clone G-A-5, Roche Molecular Biochemicals)
was performed in PBS containing 0.1% triton and 2% normal
goat serum. For BrdUrd immunohistochemistry the sections
were denatured with acid to expose the BrdUrd epitope. Apo-
ptotic cells were examined by using the terminal deoxynucleoti-
dyltransferase-mediated dUTP end-labeling assay (ApoAlert
DNA fragmentation assay kit, CLONTECH). Confocal micros-
copy was performed on a Zeiss LSM 510 machine by using
‘‘multitracking’’ settings.
Cell Counting. Unbiased absolute counts of BrdUrd-labeled
(BrdUrd) cells were made after peroxidase immunostaining in
rats and mice; in rats these were on the hemisphere ipsilateral to
the cannula. Counts were made by a blinded observer, and the
code was not broken until all the counting was completed.
Scoring of BrdUrdIII-tubulin-coimmunostained cells was per-
formed by using confocal microscope z series.
Gene Targeting. A null mutant of the mouse nNOS gene [dis-
rupted nNOS allele (KOex6)] carrying a 628-bp-long deletion of
exon 6 with adjacent intronic sequences was generated by
homologous recombination.
NOS Activity Determination. An assay for the activity of NOS by
using the conversion of [3H]arginine to [3H]citrulline was per-
formed according to standard methods.
Abbreviations: SVZ, subventricular zone; LV, lateral ventricle; RMS, rostral migratory
stream; GCL, granular cell layer; S-GCL, sub-GCL; DG, dentate gyrus; NOS, NO synthase;
nNOS, neuronal NOS; NAME, N-nitro-methyl-L[D]-arginine methyl ester; TUNEL, terminal
deoxynucleotidyltransferase-mediated dUTP end labeling; KOex6, disrupted nNOS allele;
OB, olfactory bulb.
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Results
Localization of nNOS in the Adult Brain Suggests a Role in the Control
of Neurogenesis. To examine whether NOS may be involved in the
control of adult neurogenesis, we compared sites of neurogenesis
in the adult rat brain with the sites of NOS expression (17). We
used immunohistochemical detection of nNOS and NADPH-
diaphorase histochemical staining for NOS in conjunction with
labeling cells in S phase with BrdUrd. Strong diaphorase staining
was seen in the cell bodies and the processes of the medium-sized
aspiny interneurons in the forebrain and midbrain, in agreement
with numerous reports (17, 18). A dense network of diaphorase-
positive fibers were seen throughout most parenchymal areas
and were particularly dense in the striatum.
Both the SVZ and the RMS neurogenic regions exhibit very
little diaphorase staining in comparison with the surrounding
parenchyma. In contrast, the distribution of BrdUrd cells was
limited to the SVZ and RMS, whereas surrounding parenchyma
showed very few labeled cells (Fig. 1 a and b, bracketed areas).
We confirmed the notion that NOS cells are largely excluded
from zones of active neurogenesis by staining brain sections with
anti-nNOS antibodies (Fig. 1 c and d). Whereas numerous
BrdUrd cells were seen in the SVZ and the RMS, cell bodies
of strongly nNOS cells were predominantly located outside of
these neurogenic areas (Fig. 1 c and d, arrows). Some of the
processes of the nNOS cells intermingled with BrdUrd cells
in the SVZ (Fig. 1 b and c, arrowheads) and RMS.
These data demonstrate that the areas of active neurogenesis
in the adult brain are largely free of, but closely apposed by,
NOS-expressing cells. This distribution suggests a link between
NO signaling and control of cell division in the neurogenic areas
of the brain.
NOS Inhibition Causes Increased Cell Proliferation in Neurogenic Zones
of Adult Brain. To address the role of NO during adult neuro-
genesis, we introduced a specific inhibitor of NOS, L-NAME,
into the LV of the adult rat brain using osmotic minipumps (19).
This compound is a competitive inhibitor of NOS with slow
kinetics for binding and reversal and an 10-fold higher affinity
for the constitutive NOS isoforms (nNOS and endothelial NOS)
over inducible NOS (12). The zone of infusion into the LV was
immediately proximal to the anterior SVZ, the major site of
adult neurogenesis (Fig. 2A a and b). This infusion of L-NAME
or its inactive enantiomer D-NAME was accompanied by i.p.
injections of BrdUrd (Fig. 2 Ac). The brains then were sectioned
and analyzed for BrdUrd incorporation and for the expression of
phenotype-specific markers (5, 11, 20, 21).
We found a robust and significant (P  0.05, Mann–Whitney
test) increase in the number of BrdUrd cells in neurogenic
regions (Fig. 2B and Table 1): the SVZ (58.4%), RMS (39.2%),
and olfactory bulb (OB) (17.1%). A strong increase in the
number of BrdUrd cells was also evident in the GCL and the
S-GCL of the DG (68.5%, P  0.05). We also saw a significant
Fig. 1. NOS localization in the brain suggests a role for control of neuro-
genesis. (a and b) Histochemical detection of NADPH-diaphorase (blue stain-
ing) and immunochemical detection of BrdUrd (brown staining). Note that
there is significantly less diaphorase staining, representing NOS enzyme, in the
bracketed areas, which mark the prolific neurogenic regions of the SVZ and
RMS. (c and d) Double labeling of nNOS (red) and BrdUrd (green) cells in the
SVZ (c) and RMS (d). Note that bodies of nNOS-expressing neurons lie outside
of the SVZ and RMS, whereas processes run along, but rarely cross, the
boundaries of the neurogenic BrdUrd areas. Brackets indicate areas of lower
NOS staining in the SVZ (a and c) and RMS (a and b) as compared with
neighboring parenchyma. In all panels the arrows indicate examples of cell
bodies of NOS neurons, and arrowheads show varicose NOS processes that
are proximal to dividing cells (c and d). (Insets) Anatomical position of pho-
tomicrographs of sagittal rat brain sections. cc, corpus callosum; ctx, cortex;
str, striatum. (Scale bars: a, 1 mm; b, 200 m; c and d, 50 m.)
Fig. 2. (A) Scheme of L-NAME or D-NAME infusion and BrdUrd administra-
tion. (a and b) Projection diagrams of the relationship of the infusion point
into the LV of the rat brain showing anatomy including the SVZ, RMS, LV, OB,
and DG. (c) The protocol for administration of BrdUrd and L- or D-NAME in
relation to the time for surgery (S), infusion of drugs, and perfusion (P). (B)
Changes in the numbers of BrdUrd nuclei after persistent NOS inhibition.
Absolute counts of BrdUrd nuclei of different regions from serially sampled
sagittal sections of L-NAME-infused animals show increases in all areas exam-
ined when compared with D-NAME-treated animals. The ‘‘total’’ column
represents the sum of all the regions examined. The Mann–Whitney test shows
that the differences in all tested regions were significant (P 0.05; see Table
1). DG here refers to the S-GCL and GCL.
Table 1. Cells counted in sampled rat brain sections
Region D-NAME L-NAME % Increase
DG (S-)GCL 695  146 1,171  225 68.5*
SVZ 3,836  772 6,076  584 58.4*
RMS 11,646  815 16,213  2,299 39.2*
OB 18,971  934 22,223  1,791 17.1*
All counted regions
above together
38,694  2,517 52,269  3,704 35.1*
Average number of BrdUrd cells for three brains in each treatment the
standard deviation. The total number of BrdUrd cells counted in all six brains
was 272,890.
*Statistical significance (P  0.05) using the Mann–Whitney test.
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increase in proliferation in the nonneurogenic regions of the
striatum (85.7%, P  0.005) and the remaining (non-DG)
hippocampus (70.3%, P  0.02). In control experiments we
showed that L-NAME was an effective inhibitor for the entire
period of the experiment and that prolonged infusion of L-
NAME did not affect the distribution of NOS as revealed by
NADPH-diaphorase histochemistry or nNOS immunocyto-
chemistry (data not shown). Together our results are consistent
with the notion that inhibition of NOS in vivo causes increased
proliferation in neurogenic zones of the adult brain.
To test whether the observed changes were induced in re-
sponse to damage to the brain tissue invoked by the experimental
procedures (4, 22, 23), we looked for changes in the distribution
of glial cells among the BrdUrd cells. We examined the
differences in programmed cell death between brains of animals
either treated with inhibitor or control solution or left untreated.
We found that there was an increase in the number of BrdUrd
cells expressing glial fibrillary acidic protein only in the imme-
diate vicinity of the cannula in the brain parenchyma of both L-
and D-NAME-treated animals, which is consistent with activated
astrocytes being born or migrating to the site of trauma induced
by cannulation. However, these changes were limited to the path
of the cannula, they were not observed in the areas used to derive
the data in Fig. 2B and were not different in animals treated
either with NOS inhibitor or its inactive counterpart (data not
shown), suggesting that the changes presented in Fig. 2B and
Table 1 were not caused by a damage response.
The increase in the number of BrdUrd cells after exposure
to NOS inhibitor may be a result of increased cell division or
decreased cell death. To address this issue we examined the
extent of apoptosis in the SVZ and the RMS by using the
TUNEL assay. We did not observe differences in the number or
distribution of TUNEL-positive cells between the animals ex-
posed to NOS inhibitor and control animals either exposed to
inactive enantiomer or left untreated (Kruskal–Wallis test, P 
0.05). The fractions of TUNEL-positive cells in the SVZ and the
RMS of L-NAME-treated animals were 1.43% and 0.82%,
respectively, and were not significantly different from the per-
centages obtained with the untreated or D-NAME-treated an-
imals; they were also consistent with the published data on
apoptosis in the SVZ and RMS (7). Together, these experiments
indicate that the increased number of BrdUrd cells seen after
NOS inhibition is not a reflection of decreased programmed cell
death but is a result of increased cell division.
The Phenotypic Fate of New Cells Generated After NOS Inhibition
Matches Those Normally Produced. To determine the fate of new
cells generated in the adult brain after exposure to NOS
inhibitor, we identified the phenotype of newly generated cells
in neurogenic regions by using cell-type-specific markers. We
stained brain sections with BrdUrd-specific antibody and an
antibody against neuron-specific III-tubulin, to identify newly
generated neurons. We used confocal microscopy to identify
III-tubulinBrdUrd double-labeled cells (5) in selected zones
along the SVZ and the RMS (Fig. 3); these zones reflect the
migration of newly generated neurons from the LV to the OB.
In the ventral aspects of the anterior SVZ (zone 1), few BrdUrd
nuclei (10%) also stained for III-tubulin. The degree of
colocalization increased in more dorsal regions of the anterior
SVZ and reached66% in the most proximal region of the RMS
(zone 4) and87% in more distal regions (zone 5). The majority
of the BrdUrd cells (80–90%) along the RMS (zones 5–7) and
in the OB (zone 8) also expressed III-tubulin, indicating that
most of the newly generated cells in these areas are colabeled
and undergoing neuronal differentiation. In none of the exam-
ined zones were there any significant differences in III-tubulin
BrdUrd colocalization between data derived from experimental
(L-NAME) and control (D-NAME) animals. These results
suggest that introduction of NOS inhibitors increased prolifer-
ation of neuronal progenitors without altering the phenotype of
the cells being generated.
Similarly, in the DG of the hippocampus, NOS inhibition
resulted in a significant increase in the number of BrdUrd cells
in the S-GCL and GCL (Fig. 2B and Table 1), and the fraction
of cells labeled with III-tubulin among BrdUrd cells was
unchanged (Figs. 4 and 5c). The increase in the number of
BrdUrd cells in the DG (Fig. 2B) was accompanied by a
significant increase in the volume of the GCL in the sampled
sections (27%, P  0.05, Mann–Whitney test; Fig. 5a) (although
not in the density of BrdUrd cells; Fig. 5b), suggesting that new
cells induced here directly contribute to the cytoarchitecture of
the hippocampus. Thus, NOS inhibition stimulated hippocampal
neurogenesis in the adult brain. Together, our results demon-
strate that suppression of NOS activity augments the generation
of new neurons in the adult brain.
Targeted Disruption of the nNOS Gene Results in an Increase in
Proliferation in Neurogenic Zones. To confirm that NO may serve
as a negative regulator of cell division in the adult brain, we
decided to complement and extend our pharmacological studies
with genetic investigations. Because nNOS is the enzyme re-
sponsible for producing the majority of NO in the adult mam-
malian brain (24), we decided to create a loss-of-function (null)
mutant of the nNOS gene by targeting the essential heme-
binding site of the nNOS enzyme (25, 26); this site is largely
encoded by the sixth exon of the mouse nNOS gene (Fig. 6Aa).
Mice with a mutated nNOS gene have been generated previ-
ously by targeting the second exon of the gene (24) (which does
not encode catalytically important regions), and these animals
have become valuable tools for studying the role of nNOS.
However, the use of alternative promoters and splice sites in
these mice results in the expression of a number of nNOS RNA
and protein isoforms and concomitant production of NO in the
Fig. 3. NOS inhibition does not change the fate of cells born in the SVZ and
RMS and destined for the OB. A highly schematic diagram of neurogenic zones
in adult rodent brains is shown (Upper) to identify the zones for the histogram
(Lower). The percentage of cells that have incorporated BrdUrd and express
the neuronal marker III-tubulin was compared in several arbitrarily defined
zones along the SVZ, RMS, and OB for L-NAME-treated and control (D-NAME-
treated) animals. Scoring was performed by using confocal z series of images
through the sections with orthogonal projections as shown for the data in Fig.
4. There was no statistically significant difference between these treatments
for each zone tested, suggesting that the choice of neuronal fate by the
majority of new cells in these regions was not affected despite the numbers of
new cells being significantly increased in L-NAME-treated animals (Fig. 2B).
Mann–Whitney test: P  0.121, 0.154, 0.827, 0.077, 0.275, 0.105, 0.653, and
0.513 for zones 1–8, respectively.
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brain by residual nNOS activity (24, 27, 28). To generate a null
mutant of nNOS we targeted exon 6 of the gene. We tested
several nNOS deletion constructs and found that in-frame
removal of exon 6 leads to complete loss of enzymatic activity
after transfection into cultured cells (data not shown). Thus, we
generated a targeting construct by replacing exon 6 and the
adjacent intronic sequences with the neomycin phosphotrans-
ferase gene and used it to produce homozygous mutant mice
deficient in nNOS activity (KOex6 mice; Fig. 6 Ab–Ae). Full-
length nNOS mRNA was not detected in these mice when using
RT-PCR amplification (Fig. 6Ba), although low levels of tran-
scripts lacking exon 6 were found in the brain (data not shown).
Western blot analysis with antibodies to either the amino- or
carboxyl-terminal region of nNOS failed to detect any nNOS
protein (Fig. 6Bb). Furthermore, no diaphorase staining (Fig. 6
Bd and Be) nor nNOS immunoreactivity (Fig. 6Bf ) was seen in
the brain of KOex6 animals. Importantly, we were able to detect
only negligible levels of NOS enzymatic activity in brain homog-
enates of KOex6 mutant mice (0.15  0.11% of the levels seen
in WT mice; Fig. 6Bc), in contrast to the animals lacking exon
2, which had a substantial level of residual NOS enzymatic
activity in the brain (up to 7% of WT level in some regions) (24).
Together, these results demonstrate that we have generated a
true null mutant of the nNOS gene with a complete loss of
function.
We used these mutant mice to examine the role of NO during
adult neurogenesis. We labeled dividing cells with BrdUrd and
analyzed sections of adult KOex6 brains for the number and
distribution of BrdUrd cells. We found a significant (P  0.05,
Mann–Whitney test) increase in the number of BrdUrd-stained
nuclei in the neurogenic regions of KOex6 mouse brains as
compared with their WT littermates: 23.7% in the SVZ, 41.8%
in the RMS, 19.9% in the OB, and 32.7% in the DG (Fig. 7 and
Table 2). These results demonstrate that cell division in the
neurogenic areas of the adult brain is regulated by the produc-
tion of NO, paralleling the data obtained when introducing
inhibitors of NOS into the rat brain.
When the distribution of BrdUrd cells was examined in the
brains of KOex6 mice, the changes in cell proliferation evoked
by the mutation were particularly obvious: A strong increase in
the number of BrdUrd cells was clearly evident in the OB,
RMS, and DG. Interestingly, not only did the RMS contain a
higher number of dividing cells, but some of these cells appeared
to be migrating away from the RMS toward the cortex; many of
them appeared grouped into strings that extended into the
corpus callosum (data not shown).
Similar results were thus obtained by using two quite distinct
experimental paradigms (pharmacological inhibition of NOS
activity and genetic inactivation of nNOS activity), which pro-
vides strong evidence that NO is a negative regulator of cell
proliferation in neurogenic regions of the adult mammalian
brain.
Discussion
Here we report that inhibition of NOS activity augments neu-
rogenesis in the neurogenic areas of the adult brain. These
changes are due to an increase in cell division and not a decrease
in programmed cell death. Specifically, a reduction of NOS
activity stimulates production of new neurons in both the
forebrain subependyma and hippocampal DG, two regions that
generate neurons constitutively throughout adulthood. In these
regions several subpopulations of neural stem and progenitor
cells have been characterized. In particular, in the ventricular
subependyma, subpopulations of dividing neuronal progenitors
have been identified in addition to more quiescent cells with
astrocyte-like properties (29). NO signaling may help to main-
tain the quiescence of neural stem cells or to promote terminal
differentiation in advanced neuronal progenitors; NO may also
exert its antiproliferative activity at multiple points in the
neuronal differentiation cascade.
Fig. 4. New cells in the DG choose neuronal fate. (a–e) Confocal microscope
optical sections at 1.2-m intervals from the DG of an animal exposed to
L-NAME. ( f) Representative section from the DG of the control D-NAME-
treated animal. a, b, d, and e show the III-tubulin (red, Left) and BrdUrd
(green, Right) staining; c and f show merged channels. Note that the scale on
c is twice the scale on a, b, d, and e. Each cell in c is identified with a number,
and the orthogonal projection for this cell is presented on the right. In this
field of view of seven cells in the DG S-GCL, only cell number 4 does not meet
our criteria for coimmunostaining for both BrdUrd and III-tubulin as de-
scribed in Supporting Materials and Methods. The numbers of BrdUrd cells
expressing III-tubulin are quantitated in Fig. 5c. (Scale bars: c, f, and the
orthogonal projections, 20 m; a, b, d, and e, 40 m.)
Fig. 5. New cells born after NOS inhibition contribute to the GCL of the DG.
The GCL volume increased significantly in L-NAME-treated brain (a, P 0.05).
The change in number of BrdUrd cells per volume (b, density) was not
significant (P 0.127), even though there was a 68.5% increase in BrdUrd cell
numbers in this region (Fig. 2B) after L-NAME treatment. The proportion of
cells expressing BrdUrd andIII-tubulin was not different between treatments
(c, P 0.564), suggesting that the fate of new cells in the DG was not changed.
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NO may be produced in an autocrine fashion by neural stem
or progenitor cells or in a paracrine fashion by surrounding cells.
Our observations that NOS neurons are largely excluded from
the neurogenic areas of the adult rat brain confirm previous
findings in mouse (30, 31) and are consistent with the notion of
paracrine signaling. NO may be produced in the layers adjacent
to the dividing cells or may be released from the processes of
nitrergic neurons within the SVZ and the RMS. The high density
of nNOS cells in nonneurogenic areas such as striatum raises
the possibility that NOS may chronically suppress a dormant
reserve of progenitor cells in such areas of the brain.
In our experiments we delivered NOS inhibitor to the ven-
tricular areas by using continuos intraventricular infusion. Less-
direct approaches to manipulate NO signaling in the organism
may affect multiple physiological responses, particularly when
used in a confounding context of organ injury; for instance, i.p.
introduction of NO donors or inhibitors on the background of
ischemia affects neurogenesis, perhaps by activating antiapopto-
tic, vascular, or systemic responses (32, 33).
The ability of NO to suppress cell division has been demon-
strated in neural development in a number of settings. NO acts
as a negative regulator of cell proliferation in the optic tectum
of the Xenopus tadpole (34). NO synthesis is required for
neurogenesis in the optic lobe of moth (35) as well as for
neuronal differentiation of cells in culture (36–38). NO also
modulates the balance between cell proliferation and cell dif-
ferentiation in systems as diverse as developing Drosophila
imaginal disks and embryos (16, 39, 40) and numerous types of
cultured cells (for review see ref. 16).
The molecular bases for the antiproliferative action of NO are
only beginning to be understood. Evidence from several exper-
imental models suggest that p21 may mediate some of the NO
Fig. 6. Targeted inactivation of the mouse nNOS gene. (A) Targeting
strategy. (a) ORF of the nNOS gene. Exons are numbered, and regions encod-
ing structural domains and cofactor-binding sites are shown. (b) Structural
organization of the nNOS locus (according to GenBank accession no.
NT039312). (c) Structure of WT allele, targeting construct, and targeted
KOex6 allele. Thick vertical bars, exons; thin vertical lines, restriction enzymes
sites (A, ApaI; E, EcoRI; N, NheI; P, PmlI); arrows, the directions of transcription
of the neomycin phosphotransferase gene (NEO) and the thymidine kinase
gene (TK); thick horizontal bars, the 3 and the 5 hybridization probes used
for Southern blot analysis; thin horizontal lines with arrowheads, ApaI and
NheI fragments detected with 3 and 5 probes, respectively. (d) Southern blot
analysis of mouse tail DNA. The 5.3- and 6.5-kb NheI fragments detected with
the 5 probe correspond to the WT allele and to the properly targeted KOex6
allele, respectively. The 12.0- and 8.2-kb ApaI fragments detected with the 3
probe correspond to the WT allele and to the properly targeted KOex6 allele,
respectively. (e) PCR analysis of mouse tail DNA with two pairs of primers for
detection of the WT allele (607-bp fragment) and the KOex6 allele (468-bp
fragment). (d and e) The sample genotype is indicated above blot or gel. (B)
Removal of exon 6 results in complete inactivation of the nNOS gene. (a)
RT-PCR analysis of total RNA isolated from whole mouse brains. A pair
of primers used detects the 661-bp cDNA product of the WT nNOS allele
(,), which is absent in KOex6() RNA sample. (b) Western blot
analysis of whole mouse brain protein extracts. Blots were probed with
antibodies specific either to the amino terminus (N-term) or carboxyl terminus
(C-term) of the nNOS. A 160-kDa protein band corresponding to the nNOS was
not detected in KOex6 () brain sample. Note that expression levels of
nNOS enzyme in WT brains were approximately two times higher than in
heterozygous brains. (c) NOS catalytic activity in whole brain protein extracts.
Note that enzymatic activity in KOex6 brain homogenates was at background
levels (0.15% of that in WT). NOS activity in heterozygous brains was 44.2%,
approximately half that of WT, which correlates with expression levels of the
Fig. 7. Increased cell proliferation in various neurogenic regions of the brain
in KOex6 adult mice. The absolute numbers of BrdUrd cells in different
neurogenic regions from serially sampled sagittal sections of KOex6 animals
show increases in all areas examined when compared with their WT litter-
mates (Table 2). The ‘‘total’’ column represents the sum of all the regions
examined. The Mann–Whitney test shows that the difference in all tested
regions was significant (*, P  0.05).
nNOS in WT and nNOS/brains according to immunoblotting data (Fig. 6Bb).
Taken together these results suggest that there is no nNOS allelic compensa-
tion in mice heterozygous for the KOex6 mutation. (d–f ) The absence of nNOS
in the brains of adult KOex6 mice is evident after diaphorase staining of the
whole brain (d) and the OB (e) and by immunohistochemistry in the OB with
anti-nNOS antibody ( f). (e and f ) Higher-power images of the regions indi-
cated by the boxes in d. (Scale bars: d, 1 mm; e–f, 100 m.) In a–f, the sample
genotype is indicated.
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action in G1 phase (37, 41). Genetic data indicate that NO
interacts with the retinoblastoma (Rb) pathway to control cell
division in Drosophila, and we have suggested that Rb protein
may be a direct target for S-nitrosylation (42). Interestingly, Rb
is one of several proteins that were found in a nitrosylated state
in a search for S-nitrosylated proteins (43). Yet another plausible
target is ornithine decarboxylase, since its S-nitrosylation may
inhibit proliferation of smooth muscle cells (41). Furthermore,
our recent data indicate that NO affects multiple checkpoints in
the cell cycle (N. Nakaya and G.E., unpublished data).
Several lines of evidence have suggested negative regulation of
adult neurogenesis (44–48), although the signals that suppress
the birth of new neurons in the adult brain remain unclear. In our
study we used two independent lines of evidence to identify NO
as one such suppressor of adult neurogenesis. Our pharmaco-
logical experiments with NOS inhibitors implicate NO as an
important suppressive signal, and the loss-of-function genetic
model confirmed that nNOS was indeed the target of our
pharmacological intervention. These findings strongly support
the role of NO as an essential negative regulator of cell prolif-
eration in the adult mammalian brain. Furthermore, they indi-
cate that adult neurogenesis may be augmented by therapeutic
intervention aimed at a clearly defined molecular target.
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Table 2. Cells counted in sampled mouse brain sections
Region WT KOex6 % Increase
DG 357  41 474  15 32.7*
SVZ 2,767  181 3,422  286 23.7*
RMS 4,467  438 6,337  363 41.8*
OB 2,188  242 2,623  81 19.9*
All counted regions
above together
9,779  542 12,886  739 31.8*
Average number of BrdUrd cells for three brains of each genotype (2-
month-old females)  the standard deviation. The total number of BrdUrd
cells counted in all six brains was 67,995.
*Statistical significance (P  0.05) using the Mann–Whitney test.
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